Affordable Insulin Costs: The Impact of Medicare Part D Caps on America’s Diabetes Care System and the U.S. Diabetes Association
“While the current healthcare system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone and that needs to change,” David A. Ricks, Lilly’s chair and CEO, said in a statement. “The aggressive price cuts we’re announcing today should make a real difference for Americans with diabetes. Because these price cuts will take time for the insurance and pharmacy system to implement, we are taking the additional step to immediately cap out-of-pocket costs for patients who use Lilly insulin and are not covered by the recent Medicare Part D cap.”
President Joe Biden brought up the cost cap during his annual State of the Union address last month. He called for insulin costs for everyone to be capped at $35.
The average price of insulin nearly tripled between 2002 and 2013, the American Diabetes Association says. GoodRx research shows that the trend has continued, with the average retail price of insulin rising 54% between 2014 and 2019.
In the US alone, the number of adults with diabetes has doubled over the past 20 years, and more than 37.3 million people now have it, according to the US Centers for Disease Control and Prevention. Almost 100 million people in the United States are prediabetes, a condition in which the level of blood sugar in the bloodstream is not high enough for a diagnosis of type 2 diabetes. This can cause diabetes.
When a person eats, their body breaks down food, mostly into sugar. The key that allows sugar to spark cells in the body is the pancreas releasinginsulin, which works as a key that lets the sugar into the bloodstream. If diabetes keeps sugar in the bloodstream for a long time, it can lead to serious diseases such as heart problems and blindness. In 2019, diabetes was the seventh leading cause of death in the US, according to the American Diabetes Association.
How Much Does GoodRx Describe Insulin Cost? How Discounted Retail Prices Driven Down the Cost of Overhead Instability
The US Food and Drug Administration’s approvals of generic insulin and biosimilars – drugs similar to original versions that can be made differently or with slightly different substances – have driven down the price at least somewhat, according to GoodRx.
Ricks told Don Lemon that they wanted to take away the affordability challenges of the disease, by getting everyone to meet us at this point.
Also that year, Novo Nordisk collaborated with Walmart to sell private-label analog insulin at a deep discount. The cash price of brandedinsulin is 75% off with the Walmart’s Relion NovoLog and FlexPens.
LUPKIN: For people who don’t have insurance, this is huge. So Marston lost insurance in her 20s and had to move, give away her dog. Her insulin cost her more than a thousand dollars a month. So for people with insurance, what they pay out of pocket at the pharmacy counter – a co-pay – can be affected by the list price. So there could also be some lower co-pays.
What did Eli Lilly do before? A question about how insurance companies lost $3 billion in a year after the discovery of insulin, and how many doctors died from it?
Lilly’s planned cuts “could actually provide some substantial rice relief,” said Stacie Dusetzina, a health policy professor at Vanderbilt University who studies drug costs.
The federal government started capping the amount of money that can be spent on Medicare for patients who are 65 years old or older in January.
American Diabetes Association CEO Chuck Henderson said in a statement he applauded the steps Lilly was taking and called for other insulin makers to also cap patient costs.
People with Type 1 diabetes must take insulin every day to survive. According to the American Diabetes Association, there are 8 million Americans with the disease.
Drugmakers may be seeing “the writing on the wall that high prices can’t persist forever,” said Larry Levitt, an executive vice president with the nonprofit Kaiser Family Foundation, which studies health care.
Indianapolis-based Eli Lilly and Co. became the first company to commercialize insulin in 1923, two years after University of Toronto scientists discovered it. The drugmaker’s reputation was built around producinginsulin as it branched into cancer treatments and other drugs.
Humulin and Humalog and its authorized generic brought in a total of more than $3 billion in revenue for Lilly last year. They rang up more than $3.5 billion the year before that.
CHANG: Why did Eli Lilly not take this step before? I asked David Ricks, the CEO of Eli Lilly. Problems in the health care market were the focus. Can you just tell me more about that?
I think society has aContract with it that while they are expensive, insurance should cover them and help shield them from that cost. And when they become cheap, everybody wins for reasons that are difficult to explain. That does not happen with insulin. So we’re taking these actions independent of those external effects.
CHANG: I want to ask you a question about some stories that we have heard over the course of time. Alec Raeshawn Smith, a young man who died from diabetes because of his mother’s insurance, was reported on by NPR and other news organizations. His family believes that he was rationing his insulin because it was just too expensive. What do you say to families like his right now?
The words “ricks” were used. Yeah. I’m sorry that something like that would have happened. It shouldn’t have happened. There were ways to prevent it, but they weren’t enacted. Now those cases should be fewer. Our goal is to eliminate that situation. Health care has been complicated but it has always been. Automatic discounts should occur even without insurance after today’s announcement. We’re taking steps, we’re learning, and we’re improving, so no one should have to ration theirinsulin, that’s what I would say.
NPR Program: An Overview of Biden’s Inflaton Reduction, and the Case for Expending Medicare to Endocrinologists
A rush deadline is when NPR transcripts are created. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The audio recording is the authoritative record of NPR programming.
Part of the inflation reduction act, the co-pays for Medicare for endocrinologists are included. The Biden administration is now pushing to expand that to people with commercial insurance as well.
CHANG: Well, companies don’t often make decisions that they know will hurt their bottom lines, right? So I have to wonder, does it seem like this decision could cost Eli Lilly money?
RICHARD EVANS: Rather than putting the product in there, you know, for a dollar and then having it knock around and at the end of the day, after rebates and concessions and all that, you’re making 15 to 30 cents, depending on the product, why not just sell it for that 15 or 30 and not bother with the rebates at all?
There is a catch. The PBM doesn’t treat all drugs the same. Drugs that pay a higher rebate may be more attractive to patients, if the co-pay is kept low. Making people jump through hoops for drugs can tilt the field against them, and also raise their co-pays. So without…